Eradicating Malaria in Africa: Potentials and Challenges of Vaccine Deployment

The necessity of preventive and chemotherapeutic interventions to curb the virulence of malaria has arisen due to its status as a leading burden of illness in low and middle-income countries. Malaria accounts for a significant portion of all cases and deaths, particularly in the African region, where it caused 94% of cases and 95% of deaths in 2022, according to the World Health Organization. As the Global Goals target of 2030 approaches, it is crucial to review novel approaches to combat malaria and the potential challenges that might arise, especially in the deployment of vaccines in low and middle-income countries. This paper focuses on reviewing the top two vaccines for malaria prevention, their efficacy, and the challenges that might arise in their deployment in low- and middle-income countries. Although vaccine usage has significant potential for malaria prevention, this paper suggests that there are still considerable challenges in vaccine development and large-scale production of malaria vaccines in low- and middle-income countries due to limited funding resources. Additionally, public enlightenment programs and awareness-raising sessions on the benefits of vaccines are necessary to correct misconceptions about vaccines before deployment.